Jazz Pharmaceuticals Ireland Ltd.

Avadel's action against Jazz alleging breach of confidentiality agreements, trade-secret misappropriation, correction of inventorship under 35 U.S.C. § 256, and antitrust counterclaims, relating to subject matter Avadel alleges Jazz copied into its patents including the '488 patent. Jazz's motion to dismiss and motions to stay were denied. Resolved by the October 2025 global settlement and dismissed with prejudice.

Antitrust class action concerning Xyrem that cited the '730 patent as an Orange Book REMS patent. It was terminated and transferred into the In re Xyrem MDL.

Antitrust/pay-for-delay class action listing U.S. 7,895,059 among the Orange Book patents at issue. The case was terminated July 22, 2020.

Xyrem antitrust action filed in N.D. Ill. and terminated July 22, 2020 when transferred to the Xyrem MDL. US 7,765,107 is listed among the patents at issue in the narrative.

Class action antitrust suit by UFCW Local 1500 Welfare Fund against Jazz and others in E.D.N.Y. It alleges the '106 patent was improperly listed in the Orange Book and invalid.

Petition by Amneal Pharmaceuticals LLC challenging the '306 patent. The Board did not institute review on the merits; cited as Amneal Pharms. LLC v. Jazz Pharms. Ireland Ltd., 2016 WL 5222883 (PTAB July 28, 2016).

Petition by Ranbaxy, Inc. challenging the '306 patent. The proceeding settled per Google Patents.

Petition by Par Pharmaceutical, Inc. challenging the '306 patent. The Board did not institute review on the merits, decision Apr 12, 2016.

2020 antitrust suit against Jazz listed among the cases citing the related Xyrem patent portfolio, including the ’506 patent.